NEW YORK (GenomeWeb) – Roka Bioscience today priced its initial public offering of 5 million shares at $12 per share, raising gross proceeds of $60 million.

The Warren, NJ-based firm, which makes molecular diagnostic tests for foodborne pathogens, will begin trading today on the Nasdaq Global Market under the ticker symbol "ROKA". The share price is below the previously anticipated range of $14 to $16 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.